pyrazofurin and Inflammation

pyrazofurin has been researched along with Inflammation* in 1 studies

Trials

1 trial(s) available for pyrazofurin and Inflammation

Article	Year
Phase I study of pyrazofurin in refractory acute myelogenous leukemia. Cancer treatment reports, 1978, Volume: 62, Issue:10 Pyrazofurin was administered to 17 patients with refractory acute myelogenous leukemia in 5-day courses every 2-3 weeks. Doses ranged from 30 to 60 mg/m2/day. Severe stomatitis and dermatitis occurred at doses effective in reducing the leukocyte count (45 mg/m2). Reduction of the dose to 30 mg/m2 resulted in less toxicity and less chemotherapeutic effect. These results indicate that at tolerable doses given as described, pyrazofurin had little antileukemic activity in acute myeologenous leukemia. Topics: Adult; Aged; Amides; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Eruptions; Drug Evaluation; Female; Humans; Inflammation; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Mucous Membrane; Pyrazoles; Ribonucleosides; Ribose	1978

Article

Year

Phase I study of pyrazofurin in refractory acute myelogenous leukemia.

Cancer treatment reports, 1978, Volume: 62, Issue:10

Pyrazofurin was administered to 17 patients with refractory acute myelogenous leukemia in 5-day courses every 2-3 weeks. Doses ranged from 30 to 60 mg/m2/day. Severe stomatitis and dermatitis occurred at doses effective in reducing the leukocyte count (45 mg/m2). Reduction of the dose to 30 mg/m2 resulted in less toxicity and less chemotherapeutic effect. These results indicate that at tolerable doses given as described, pyrazofurin had little antileukemic activity in acute myeologenous leukemia.

Topics: Adult; Aged; Amides; Antibiotics, Antineoplastic; Clinical Trials as Topic; Drug Eruptions; Drug Evaluation; Female; Humans; Inflammation; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Middle Aged; Mucous Membrane; Pyrazoles; Ribonucleosides; Ribose

1978